Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Long-Time Follow-up of 888 Patients Diagnosed with CLL on a Single Center: Comorbidities, Time-to-Treatment and Comparison between Treated and Untreated Patients

Felix Keil, MD, Lisa Obenaus, BSc, Victor Rathkolb, MD, Michael Leiner, MD, Robert Spörk, MSc, Elisabeth Koller, MD, Ernst Forjan, MD, Ralph Simanek, MD, Michael Panny, MD, Daniel Lechner, MD, Alexandra Böhm, MD, Anabel Schönmetzler, MD, Theresia Kornberger, MD, Thomas Noesslinger, MD

Blood (2019) 134 (Supplement_1): 5458.

https://doi.org/10.1182/blood-2019-122024

Published: 2019

Journal Articles

Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of Real World Data from an Ongoing, National, Multi-Center, Non-Interventional Study

Daniel Lechner, MD, Richard Greil, MD, Bernd Hartmann, Maria-Theresa Krauth, MD, Heinz Gisslinger, Ursula Vogl, Leopold Ohler, Hildegard T. Greinix, MD, Siegfried Sormann, Johannes Andel, Ernst Rechberger, Hermine Agis, MD

Blood (2018) 132 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2018-99-116292

Published: 2018

Journal Articles

Ixazomib in Combination with Thalidomide and Dexamethasone for Induction and Ixazomib Maintenance Therapy Overcomes High-Risk Cytogenetics (but not of 1q21 Gain) in Relapsed/Refractory Multiple Myeloma — AGMT_MM1

Heinz Ludwig, MD, Wolfram Pönisch, MD, Stefan Knop, Martin Schreder, MD, Daniel Lechner, MD, Roman Hajek, MD PhD, Eberhard Gunsilius, MD, Karl Jochen Krenosz, MD, Andreas Petzer, MD, Katja Weisel, MD, Hermann Einsele, MD PhD, Richard Greil, MD, Niklas Zojer, MD

Blood (2018) 132 (Supplement 1): 3275.

https://doi.org/10.1182/blood-2018-99-118061

Published: 2018

Journal Articles

Multiple Myeloma and Renal Impairment: Analysis of Induction Therapy Strategies and Outcome after Autologous Stem Cell Transplantation

Thomas Reiter, MD, Marlies Antlanger, Alexandra Böhm, Wolfgang Lamm, Max Gornicec, Ella Willenbacher, MD, David Nachbauer, Werner Rabitsch, Daniel Lechner, MD, Hildegard Greinix, Felix Keil, MD, Heinz Gisslinger, Hermine Agis, MD, Maria-Theresa Krauth, MD

Blood (2017) 130 (Supplement 1): 5424.

https://doi.org/10.1182/blood.V130.Suppl_1.5424.5424

Published: 2017

Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance

Heinz Ludwig, MD, Wolfram Pönisch, MD, Alexander Egle, MD, Stefan Knop, MD, Martin Schreder, MD, Daniel Lechner, MD, Roman Hajek, Eberhard Gunsilius, Michael A. Fridrik, MD, Andreas Petzer, MD, Katja C. Weisel, Dietger Niederwieser, MD, Axel Hinke, PhD, Richard Greil, MD, Niklas Zojer, MD

Blood (2017) 130 (Supplement 1): 1857.

https://doi.org/10.1182/blood.V130.Suppl_1.1857.1857

Published: 2017

Journal Articles

Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera Study

Heinz Gisslinger, MD, Veronika Buxhofer-Ausch, MD, Josef Thaler, MD, Ernst Schloegl, MD, Guenther A. Gastl, MD, Dominik Wolf, MD, Robert Kralovics, PhD, Bettina Gisslinger, Daniel Lechner, MD, Karin Strecker, MD, Alexander Egle, Thomas Melchardt, MD, Sonja Burgstaller, MD, Ella Willenbacher, MD, Michael Zoerer, PhD, Oleh Zahriychuk, MD, MSc, Christoph Klade, PhD, Richard Greil, MD

Blood (2013) 122 (21): 4046.

https://doi.org/10.1182/blood.V122.21.4046.4046

Published: 2013

Journal Articles

AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)

Heinz Gisslinger, MD, PhD, Robert Kralovics, Bettina Gisslinger, Daniel Lechner, MD, Veronika Buxhofer-Ausch, MD, Karin Strecker, MD, Guenther Gastl, MD, Ella Willenbacher, MD, Richard Greil, MD, Alexander Egle, MD, Thomas Melchardt, MD, Sonja Burgstaller, MD, Ernst Schloegl, MD, Franz-Josef Tarmann, MSc, Michael Zoerer, PhD, Christoph Klade, PhD, Oleh Zahriychuk, MD, Josef Thaler, MD

Blood (2012) 120 (21): 175.

https://doi.org/10.1182/blood.V120.21.175.175

Published: 2012

Journal Articles

Endothelial Cell-Derived Microparticles in the Pathogenesis of Chemotherapy-Associated Hypercoagulability.

Daniel Lechner, MD, Marietta Kollars, Sabine Eichinger, MD, Paul Alexander Kyrle, MD, Ansgar Weltermann, MD

Blood (2006) 108 (11): 1457.

https://doi.org/10.1182/blood.V108.11.1457.1457

Published: 2006

NARROW

Long-Time Follow-up of 888 Patients Diagnosed with CLL on a Single Center: Comorbidities, Time-to-Treatment and Comparison between Treated and Untreated Patients

Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of Real World Data from an Ongoing, National, Multi-Center, Non-Interventional Study

Ixazomib in Combination with Thalidomide and Dexamethasone for Induction and Ixazomib Maintenance Therapy Overcomes High-Risk Cytogenetics (but not of 1q21 Gain) in Relapsed/Refractory Multiple Myeloma — AGMT_MM1

Multiple Myeloma and Renal Impairment: Analysis of Induction Therapy Strategies and Outcome after Autologous Stem Cell Transplantation

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance

Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera Study

AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)

Endothelial Cell-Derived Microparticles in the Pathogenesis of Chemotherapy-Associated Hypercoagulability.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only